Novo Nordisk A/S Key Target Audience Market Players Investors End-users Government Authorities Consulting and Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In January 2023, Semaglutide (Wegovy- Novo Nordisk) has been licensed by the US Food and Drug Administration for the treatment of obesity in pediatric patients aged 12 and above
However, effective pharmacological therapeutic agents are still lacking
A recent study of 30,000 insured patients compared costs: 14,000 had bariatric surgery 16,000 used GLP-1 medications Total Cost Over 2 Years GLP-1 medications cost approximately $12,000 MORE , and because they must be taken long-term , costs continue to rise every year
(Kim et al., Cell Metabolism, 2018) Phase I human trials are underway, but no completed RCTs with metabolic endpoints in insulin-resistant patients have been published as of mid-2025
Posttranslational modification of Wnts mainly includes lipid modification and glycosylation, and lipid modification is performed by PORCN